Crossmark Global Holdings Inc. Buys 393 Shares of Hologic, Inc. (NASDAQ:HOLX)

Crossmark Global Holdings Inc. increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.2% in the third quarter, Holdings Channel reports. The institutional investor owned 18,101 shares of the medical equipment provider’s stock after acquiring an additional 393 shares during the period. Crossmark Global Holdings Inc.’s holdings in Hologic were worth $1,474,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the 3rd quarter worth about $25,000. Innealta Capital LLC purchased a new stake in Hologic in the 2nd quarter worth about $25,000. iA Global Asset Management Inc. bought a new stake in Hologic in the first quarter worth about $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of HOLX stock opened at $79.18 on Thursday. The firm has a market cap of $18.39 billion, a price-to-earnings ratio of 23.78, a PEG ratio of 2.52 and a beta of 0.98. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $80.84 and its 200 day moving average is $78.22.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.89 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HOLX shares. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Finally, Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.